BioCentury | Dec 31, 2020
Distillery Therapeutics

Host-directed inhibitors against the SKI complex to inhibit coronavirus, influenza, Ebola, Marburg viruses

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza virus; Ebola; infectious Host-directed therapies inhibiting SKI complex components SKIV2L, TTC37 and WDR61 could treat coronavirus, influenza virus, Ebola and Marburg virus infections. In human lung and liver...
BioCentury | Dec 5, 2019
Emerging Company Profile

Deerfield propels Civetta with $53M series A

...neuraminidase, β-propeller proteins targeted by drug development programs include the chromatin complex regulators EED and WDR5...
...large B-cell lymphoma (DLBCL). In January, Celgene Corp. gained an option to acquire a preclinical WDR5...
...Deerfield Management CEO: Bruce Goldsmith Patents: Undisclosed Targets EED - Embryonic ectoderm development WDR5 - WD repeat domain 5 Karen...
BioCentury | Feb 1, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...Triphase's preclinical molecule TRPH-395 to treat blood cancers including leukemia. The small molecule inhibitor of WD repeat domain 5 (WDR5)...
...development and commercialization if it exercises the option, O'Neill said. In October 2018, FDA listed WDR5...
...Triphase Accelerator Corp., Toronto, Ontario Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Sandi Wong TRPH-395 Celgene Corp. Triphase Accelerator Corp. WD repeat domain 5 (WDR5) Leukemia...
BioCentury | Jan 29, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...Triphase's preclinical molecule TRPH-395 to treat blood cancers including leukemia. The small molecule inhibitor of WD repeat domain 5 (WDR5)...
...development and commercialization if it exercises the option, O'Neill said. In October 2018, FDA listed WDR5...
...and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn, Obsidian deals" ). Sandi Wong Celgene Corp. Triphase Accelerator Corp. WD repeat domain 5 (WDR5) Leukemia TRPH-395...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...arginine methylation, lysine methylation, lysine acetylation or lysine demethylation. The group includes one target, WDR5...
...3; TEAD4 -TEA domain family member 4; TET2 - Tet methylcytosine dioxygenase 2; WDR5 - WD repeat domain 5...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

INDICATION: Schizophrenia; depression Cell culture studies suggest inhibiting DISC1 - FBXW7 binding could help treat schizophrenia and major depressive disorder (MDD). In human neuroprogenitor cells (NPCs) differentiated from induced pluripotent stem (iPS) cells generated from skin...
BioCentury | Jul 20, 2017
Preclinical News

FBXW7-DISC1 complex linked to schizophrenia

In a paper, researchers showed that F-box and WD repeat domain containing 7 (FBXW7; FBW7) controls levels of a scaffold protein, disrupted in schizophrenia 1 (DISC1) , which is deficient in hereditary schizophrenia. The research suggests...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BioCentury | Apr 10, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC); bone cancer Ubiquitin specific peptidase 1 (USP1); WD repeat domain 48 (WDR48; UAF1) Cell-based studies suggest inhibiting the USP1-UAF1 complex...
BioCentury | Jan 10, 2013
Distillery Therapeutics

Indication: Cancer

...mixed-lineage leukemia (MLL; HRX); WD repeat domain 5 (WDR5) In vitro studies identified inhibitors of the protein-protein interaction between WDR5...
...help treat leukemias. In an enzymatic assay, peptide inhibitors of the MLL binding site on WDR5...
Items per page:
1 - 10 of 15